22.37
+0.85(+3.95%)
Currency In USD
| Previous Close | 21.52 |
| Open | 21.1 |
| Day High | 22.45 |
| Day Low | 21.02 |
| 52-Week High | 46.99 |
| 52-Week Low | 14.8 |
| Volume | 1.6M |
| Average Volume | 877,779 |
| Market Cap | 1.7B |
| PE | -15.87 |
| EPS | -1.41 |
| Moving Average 50 Days | 24.22 |
| Moving Average 200 Days | 31.43 |
| Change | 0.85 |
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
GlobeNewswire Inc.
4 hours ago
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
GlobeNewswire Inc.
Apr 24, 2025 12:00 PM GMT
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladde
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
GlobeNewswire Inc.
Mar 31, 2025 12:00 PM GMT
- Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncology’s clinical trial program, including translatio